Endothelial dysfunction and chronic kidney disease: treatment options

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Endocrinology

Background:

• Endothelial cells maintain vascular homeostasis but are compromised by traditional cardiovascular disease risk factors.
• Chronic kidney disease (CKD) patients exhibit significantly higher cardiovascular disease (CVD) risk and mortality, with endothelial dysfunction being a common early feature.
• Standard treatments like statins and thiazolidinediones show limited efficacy in improving endothelial function and reducing CVD risk in CKD patients.

Purpose of the Study:

• To explore the role of endothelial dysfunction in CKD and its implications for cardiovascular complications.
• To evaluate the potential of Vitamin D Receptor (VDR) activators in mitigating endothelial dysfunction and improving survival in CKD patients.
• To assess the effectiveness of renin-angiotensin system inhibitors in slowing CKD progression, potentially via endothelial function improvement.

Main Methods:

• Review of existing literature on endothelial dysfunction in CKD and the efficacy of various therapeutic agents.
• Analysis of clinical study results concerning lipid-lowering agents, antidiabetic agents, and VDR activators in CKD populations.
• Examination of data on antihypertensive therapies, including ACE inhibitors and ARBs, and their impact on CKD progression and endothelial function.

Main Results:

• Traditional CVD risk factors and CKD contribute to endothelial dysfunction, characterized by imbalances in vasodilation/vasoconstriction, oxidative stress, inflammation, thrombosis, and repair mechanisms.
• Statins and thiazolidinediones demonstrate reduced efficacy in CKD patients compared to the general population.
• Vitamin D Receptor (VDR) activators are associated with improved survival in CKD patients, suggesting a role in modulating endothelial dysfunction.
• Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may slow CKD progression through mechanisms beyond blood pressure control, potentially involving improved endothelial function.

Conclusions:

• Endothelial dysfunction is a critical factor in the elevated cardiovascular risk associated with CKD.
• VDR activation therapy shows promise for improving survival in CKD patients, necessitating further randomized clinical trials.
• Targeting the renin-angiotensin system with ACE inhibitors or ARBs may offer benefits in CKD management by improving endothelial function, independent of blood pressure reduction.